Big pharma validation drives psychedelic therapy thesis
The speaker argued big pharma M&A and regulatory momentum validate psychedelic medicine as a structural threat to traditional antidepressants.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.